mRNA Multipeptide-HLA Class II Immunotherapy for Melanoma

Area of Science:

• Immunology
• Oncology
• Computational Biology

Background:

• Human Leukocyte Antigen (HLA) Class II molecules present peptides to CD4+ T cells, initiating immune responses.
• High-affinity binding of peptides to HLA-II is crucial for T cell activation and subsequent immune functions.
• Melanoma-associated proteins contain peptides with potential as antitumor agents when presented by HLA-II.

Purpose of the Study:

• To computationally identify high-affinity peptide-HLA Class II (pHLA-II) complexes from melanoma-associated proteins.
• To discover potent epitopes for developing novel cancer immunotherapies.

Main Methods:

• In silico prediction of binding affinity (IC50) for all possible 15-mer peptides from 15 melanoma antigens against 192 common HLA-II molecules.
• Analysis of 665,472 pHLA-II pairs to identify those with strong predicted binding affinity (PBBA IC50 < 50 nM).

Main Results:

• Identified 5941 pHLA-II pairs with strong predicted binding affinity, representing 0.89% of all tested pairs.
• These high-affinity binders originated from 117 HLA-II alleles and 679 distinct epitopes.
• The identified epitopes and their corresponding HLA-II molecules are suitable for multipeptide vaccine development.

Conclusions:

• The identified 679 high-antigenicity epitopes can be used to design effective cancer vaccines.
• Administration of these epitopes, alone or with HLA-II molecules, can stimulate CD4+ T helper cells, augment CD8+ T cell functions, and induce antitumor antibodies.
• This approach holds promise for treating melanoma and other solid tumors, potentially enhanced by immune checkpoint inhibitors.